Literature DB >> 22183072

MAGE-A3 expression is an adverse prognostic factor in diffuse large B-cell lymphoma.

Irma Olarte1, Adolfo Martinez, Christian Ramos-Peñafiel, Humberto Castellanos-Sinco, Jorge Zamora, Juan Collazo-Jaloma, Mario Gutiérrez, Laila Gutiérrez-Kobeh, Pedro Chavez-Olmos, Hugo Manzanilla, Efraín Garrido-Guerrero, Rosa M Ordoñez-Razo, Enrique I Miranda.   

Abstract

This study evaluates the prognostic value of MAGE-A3 expression in 28 diffuse large B-cell lymphoma (DLBCL) patients. A significant association was observed between MAGE-A3 expressions, assessed by quantitative real-time RT-polymerase chain reaction (PCR), with advanced stages of disease (P < 0.05). Elevated serum lactate dehydrogenase (LDH) levels and International Prognostic Index (IPI) score were significantly higher in MAGE-A3-positive patients (P = 0.025 and P = 0.004, respectively). Expression of MAGE-A3 was associated with poor response to treatment and a significantly shorter overall survival (P < 0.001). Our data address new information in the association of MAGE-A3 expression and poor prognosis in DLBCL patients.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22183072     DOI： 10.1179/102453311X13085644680384

Source DB:  PubMed          Journal:  Hematology        ISSN： 1024-5332            Impact factor:   2.269


  6 in total

1.  Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen.

Authors:  Takashi Fukuyama; Taiga Yamazaki; Tomoko Fujita; Takayuki Uematsu; Yoshinobu Ichiki; Hiroshi Kaneko; Tatsuo Suzuki; Noritada Kobayashi
Journal:  Tumour Biol       Date:  2012-07-07

2.  Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress.

Authors:  Leticia Y Peche; María F Ladelfa; María F Toledo; Miguel Mano; Julieta E Laiseca; Claudio Schneider; Martín Monte
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

3.  Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.

Authors:  Xinfeng Chen; Liping Wang; Jinyan Liu; Lan Huang; Li Yang; Qun Gao; Xiaojuan Shi; Jieyao Li; Feng Li; Zhen Zhang; Song Zhao; Bin Zhang; Pierre Van der Bruggen; Yi Zhang
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

4.  MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.

Authors:  Anthony P Conley; Wei-Lien Wang; John A Livingston; Vinod Ravi; Jen-Wei Tsai; Ali Ali; Davis R Ingram; Caitlin D Lowery; Christina L Roland; Neeta Somaiah; Patrick Hwu; Cassian Yee; Vivek Subbiah; Andrew Futreal; Alexander J Lazar; Shreyaskumar Patel; Jason Roszik
Journal:  Cancers (Basel)       Date:  2019-05-15       Impact factor: 6.639

5.  MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.

Authors:  Aaron Chen; Alexis L Santana; Nicole Doudican; Nazanin Roudiani; Kristian Laursen; Jean-Philippe Therrien; James Lee; Diane Felsen; John A Carucci
Journal:  PLoS One       Date:  2020-11-23       Impact factor: 3.240

6.  Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer.

Authors:  Shi Jin; Shoubo Cao; Aleksei Grigorev; Jianhua Li; Qingwei Meng; Chunyan Wang; Meiyan Feng; Jing Hu; Feng Jiang; Yan Yu
Journal:  Cancer Manag Res       Date:  2018-07-16       Impact factor: 3.989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.